21 Aug 2017 --- TSI Group (TSI) has announced the approval of the first and only CFDA (China Food and Drug Administration) Manufacturing License for beta-hydroxy-beta-methylbutyrate (HMB) production in China. TSI’s Jiangyin Pharmaceutical facility, a wholly owned TSI Group company, received this exclusive license to produce HMB for use in Chinese food products.
